This page has been fact checked by an experienced mesothelioma Patient Advocate. Sources of information are listed at the bottom of the article.
We make every attempt to keep our information accurate and up-to-date.
Please Contact Us with any questions or comments.
Dr. David P. Carbone is a medical oncologist who specializes in treating patients with lung cancer and other thoracic malignancies at the James Cancer Hospital of the Ohio State University Comprehensive Cancer Center. Dr. Carbone is Director of the hospital’s thoracic center and co-leader of the Translational Therapeutics Program at the Ohio State University Comprehensive Cancer Center, where he focuses on genetics, targeted therapies, immunotherapy, and tumor-associated immunosuppression mechanisms.
An expert in the areas of cancer biology, cell biology, gene expression, and bioinformatics, Dr. Carbone holds the Barbara J. Bonner Chair in Lung Research. He calls lung cancer “a disease with unacceptable outcomes,” and is passionate about the promising therapies that he sees on the horizon. Dr. Carbone speaks enthusiastically about the multidisciplinary team approach in use at James Cancer Hospital and appreciates the collaboration on advanced molecular diagnostics and state-of-the-art therapeutics that allow the center to provide personalized care to patients.
Education and Career
Dr. Carbone attended Amherst College for undergraduate school, graduating summa cum laude. He received his medical degree and earned a Ph.D. in Molecular Biology and Genetics at Johns Hopkins University, then completed an Internal Medicine internship and residence at the Johns Hopkins Hospital. He completed a fellowship in Medical Oncology at the National Cancer Institute in Bethesda, Maryland.
After completing his education, Dr. Carbone was appointed Assistant Professor at the University of Texas Southwestern Medical Center. He was later recruited to Vanderbilt University where he served as Professor of Medicine, Cell Biology, and Cancer Biology as well as Director of the Experimental Therapeutics Program and the Thoracic Oncology Center at the Vanderbilt-Ingram Cancer Center. He was also the Director and Principal Investigator of the Vanderbilt Specialized Program of Research Excellence in Lung Cancer and the Strategic Partnering to Evaluate Cancer Signatures UO1 consortium.
In 2012, Dr. Carbone was asked to join Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute to direct its thoracic center. Today he serves as professor of Internal Medicine at The Ohio State University and co-leader of the Translational Therapeutics Program at the OSUCCC – James, as well as directing the Thoracic Oncology Center.
Dr. Carbone is also the president of the International Association for the Study of Lung Cancer.
Dr. Carbone has served as an investigator on multiple clinical trials, including the large phase III lung Cancer trials for the Eastern Cooperative Oncology Group. His research is focused primarily on proteomic and expression array signature development, genetics, immunotherapy, and tumor-associated immunosuppression mechanisms in lung cancer.
Dr. Carbone has authored more than 3000 peer-reviewed publications, book chapters, and articles and has served on several National Cancer Institute grant review panels. He has also served on the NCI Board of Scientific Counselors, is the co-chair of the NCI CTEP Thoracic Malignancies Steering Committee, and co-directs the Translational Immuno-Oncology Program in the Pelotonia Institute for Immuno-Oncology.Get Your FREE Mesothelioma Packet
Written by Terri Oppenheimer
Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.
Page Edited by Patient Advocate Dave Foster
Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.